Coming Soon!! At Vitro Biopharma, our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market, and ultimately, to address well-established multi-billion-dollar commercial markets. We are committed to translating innovative science into medicines that transform the lives of patients with various diseases.

We believe our 30 years of drug discovery and development has enabled us to identify and advance multiple product candidates from preclinical studies into clinical trials. Our extensive knowledge of immunology and inflammatory conditions informs our decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget. The current infrastructure within our discovery and development capabilities of Institutional Review Board (IRB) approved clinical trials in international countries, has allowed us to refine our processes and protocols, as well as, see evidence of efficacy and safety.


Product Categories

Developing innovative treatments in autoimmune disorders and inflammatory disease processes

We are a biologics company committed to translating innovative science into medicines that transform the lives of patients with various diseases.

About Vitro

Vitro Biopharma is a clinical-stage biotechnology company focused on developing Wharton’s jelly-derived cell therapies and targeting new treatments for millions of patients with rare and broad indications. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.

Biopharmaceuticals

There are multiple characteristics of umbilical cord MSCs significantly superior to those derived from adipose, bone marrow or placental tissues. Umbilical cord MSCs have superior potency by mitochondrial and immunosuppression measurement and are the youngest adult stem cells, free from age related issues, prior medical conditions and genetics. AlloRx® Stem Cells are ethically sourced and derived from the Wharton’s Jelly of the umbilical cord. Strict screening of the donor’s medical & social history is evaluated as well as rigorous testing of the donor’s tissue is preformed prior to accepting cords.

Developing Differentiated Product Candidates

Derived from the most potent stem cells measured by purity and potency, Wharton’s jelly of the umbilical cord, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our lead product candidate, AlloRx® has been used internationally to treat a variety of patients with autoimmune and inflammatory diseases, such as COPD, osteoarthritis, multiple sclerosis, Pitt-Hopkin’s, Alzheimer’s, and lupus.

Vitro Biopharma has a significant cost advantage within our patent pending, proprietary and scalable manufacturing process.

Innovative Drug Discovery

Modern cell therapy and stem cell technology are rapidly evolving and hold promise to revolutionize medicine by allowing regeneration of any type of cell within the human body. We believe our 30 years of drug discovery and development, supplying research products to world-class institutions and pharmaceutical companies, has enabled us to identify and advance multiple product candidates from preclinical studies into clinical trials. Here are some of the remarkable people we have worked with.

Science

Vitro Biopharma develops Wharton’s jelly of the umbilical cord-derived cell therapies to modulate the immune system and inflammation. Umbilical Cord MSCs are the youngest, most potent adult stem cells known, free from age related issues, prior medical conditions and genetics that come with use of adipose or bone-marrow-derived MSCs. UC-MSCs are significantly superior in multiple categories to other adult stem cells, including the ability to differentiate into neural stem cells (NSCs), adipose and bone-marrow-derived MSCs do not.

Our extensive knowledge of immunology and inflammatory conditions informs our decision making to advance the scientific and clinical path to demonstrate proof-of-concept, with the goal of achieving an efficient timeframe and cost-effective budget.

The mechanisms of action involve immunomodulation that reduces patient immune response to myelin basic protein. Negative regulation of T-cells through secretion of IDO (indolamine dioxygenase) by the conversion of tryptophan to kynurenine that directly inhibits T-cell proliferation. Further MSC-induced up-regulation of TREG cells by TGF-beta secretion from MSCs also suppresses immunity through regulation of dendritic cells. Other mechanisms include cellular repair of demyelination by cellular repair through paracrine effects that repair damaged neurons as evidenced by resolution of plaques by MRI imaging. Anti-inflammatory mechanisms are also likely including MSC-induced shift of M1 pro-inflammatory macrophages to M2 anti-inflammatory macrophages and secretion of PGE2 from MSCs that up-regulates dendritic cells to secrete anti-inflammatory cytokine IL-10 and decrease secretion of pro-inflammatory cytokines TNGF-alpha and IL-12.

Modulate Inflammation

Respond to excessive
pro‐inflammatory signals via receptors
for TNF‐α, IFN‐γ and
IL‐1β

Comparative Analysis

There are multiple characteristics of umbilical cord MSCs significantly superior to those derived from adipose, bone marrow or placental tissues.

Superior Potency

Superior potency by mitochondrial and immuno-suppression measurement.

Profile

UC-MSCs have cellular functional advantages in migration, proliferation, yield, secretion properties and viability.

Scalable Manufacturing: Key Competitive Advantage

AlloRx® Stem Cells are derived from the Wharton’s Jelly of the umbilical cord. Cords are ethically sourced and donated after a baby is born. Strict screening of the donor’s medical & social history is evaluated as well as rigorous testing of the donor’s tissue is preformed prior to accepting cords. The cords are processed in Vitro Biopharma’s ISO 7 cleanroom with strict standard operating procedures and environmental controls. Through Vitro’s proprietary technology, we convert the cells into potential therapeutics by increasing the ATP expression, viability, yield, and has been seen to be more efficacious through different indications. We have a significant cost advantage within our manufacturing process which can derive trillions of cells from one umbilical cord.

Research Products

Stem Cell Research Products & Technology

Our stem cell products and technology are based upon MSCs. We offer basic tools to support stem cell research and clinical studies of MSCs. Our products include both native MSCs and various derivatives, our MSC-Gro™ specialty cell culture media for support of growth and differentiation of MSCs. Our cell lines include native mesenchymal stem cells, Cancer-Associated Fibroblasts (CAFs) & native fibroblasts for advanced cancer research.

We have developed several novel cell culture media formulations through over 25 years of stem cell research. We now offer various formulations for both stem cells and primary cell culture that feature numerous competitive advantages. These include faster growth, resulting in significantly greater cellular yield, higher quality and potency, vastly improved stability and complete formulations without the necessity of mixing prior to use.

Biomarker profiling plays an important role in drug discovery, diagnostics and molecular medicine because the link between genes, proteins and disease. As researchers study defective proteins that cause particular diseases, their findings will help develop new drugs that either alter the shape of a defective protein or mimic a missing one.

  • Adipokine Panel 1
  • Adipokine Panel 2
  • Angiogenesis Biomarkers
  • Bone Metabolism
  • Cardiovascular Panel 1
  • Cardiovascular Panel 2
  • Cardiovascular Panel 3
  • Cardiovascular Panel 4
  • CD8+ T Cell
  • Circulating Biomarkers Panel 1
  • Circulating Biomarkers Panel 2
  • Circulating Biomarkers Panel 3
  • Cytokine Panel 1
  • Cytokine Panel 2
  • Cytokine Panel 3
  • High Sensitivity T Cell
  • IGF
  • IGF Binding Protein
  • Immunoglobuline Isotyping
  • Kidney Injury Panel 1
  • Kidney Injury Panel 2
  • Kidney Injury Panel 3
  • Kidney Injury Panel 4
  • Kidney Injury Panel 5
  • Kidney Injury Panel 6
  • Liver Protein
  • Metabolic Hormone
  • Metastatic Biomarkers